Earnings increase for Takeda
Published: 29 Jul 2011
Japan-based Takeda Pharmaceutical has recorded an increase in profit of 17.9 per cent in its financial report for the second quarter of 2011.
The company made 75.58bn yen for the period compare to 64.11bn Yen the previous year.
Operating income was also up, increasing 8.3 per cent to 116.21bn yen. Launches for the company during the quarter included hypertension treatment Edarbi (azilsartan medoxomil), with growth for multiple myeloma treatment Velcade (bortezomib) and type 2 diabetes drug Actos (pioglitazone) also contributing towards a net sales increase of 0.7 per cent.
In its outlook for future prospects, the company said it had formulated its ‘2011 - 2013 Mid-Range Plan’.
The plan states that Takeda will invest greatly in research and development that is focused on its core therapeutic areas of metabolic conditions, oncology and the central nervous system. The company will also make significant investments in emerging markets.
Recent developments include the company’s acquisition of Nycomed, which is pending review and expected to be completed by the end of September 2011.
In its review, Takeda said the Nycomed purchase would bring an “immediate and stable increase in cash flow,” as well as offering greater leverage for research and development.
Published: 29 Jul 2011
Comments are moderated and will not appear until approved by a member of the Communique team.